Multivalent compounds for crosslinking receptors and uses...

Details Multivalent compounds for crosslinking receptors and uses... Multivalent compounds for crosslinking receptors and uses...

2005-04-05

2005-04-05

Weber, Jon P. (Department: 1653)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C558S286000, C558S290000, C568S001000, C548S535000, C530S330000, C530S331000

Reexamination Certificate

active

06875737

ABSTRACT:
Synthetic crosslinking homobivalent and heterobivalent compounds have been designed and developed. These compounds are low in molecular weight, have antagonistic or agonistic activity, and induce the association between two identical or similar natural receptors (homobivalent compounds) or induce the association between two different natural receptors (heterobivalent compounds).

REFERENCES:
patent: 4318904 (1982-03-01), Shaw et al.
patent: 4443609 (1984-04-01), Oude Alink et al.
patent: 4499082 (1985-02-01), Shenvi et al.
patent: 4582821 (1986-04-01), Kettner et al.
patent: 4636492 (1987-01-01), Kettner et al.
patent: 4644055 (1987-02-01), Kettner et al.
patent: 4652552 (1987-03-01), Kettner et al.
patent: 4935493 (1990-06-01), Bachovchin et al.
patent: 4963655 (1990-10-01), Kinder et al.
patent: 5093477 (1992-03-01), Mölling et al.
patent: 5187157 (1993-02-01), Kettner et al.
patent: 5215926 (1993-06-01), Etchells, III et al.
patent: 5242904 (1993-09-01), Kettner et al.
patent: 5250720 (1993-10-01), Kettner et al.
patent: 5288707 (1994-02-01), Metternich
patent: 5296604 (1994-03-01), Hanko et al.
patent: 5329028 (1994-07-01), Ashkenazi et al.
patent: 5378624 (1995-01-01), Berenson et al.
patent: 5384410 (1995-01-01), Kettner et al.
patent: 5444049 (1995-08-01), de Nanteuil et al.
patent: 5462928 (1995-10-01), Bachovchin et al.
patent: 5506130 (1996-04-01), Peterson et al.
patent: 5527923 (1996-06-01), Klingler et al.
patent: 5543396 (1996-08-01), Powers et al.
patent: 5554728 (1996-09-01), Basava et al.
patent: 5635386 (1997-06-01), Palsson et al.
patent: 5635387 (1997-06-01), Fei et al.
patent: 5646043 (1997-07-01), Emerson et al.
patent: 158109 (1982-12-01), None
patent: 270382 (1989-07-01), None
patent: 296075 (1991-11-01), None
patent: 0356223 (1990-02-01), None
patent: 0371467 (1990-06-01), None
patent: 0471651 (1992-02-01), None
patent: 0481311 (1992-04-01), None
patent: 0615978 (1994-09-01), None
patent: 0420913 (1995-11-01), None
patent: 0688788 (1995-12-01), None
patent: WO 8903223 (1989-04-01), None
patent: WO 9116339 (1991-10-01), None
patent: WO 9117767 (1991-11-01), None
patent: WO 9212140 (1992-07-01), None
patent: WO 9217490 (1992-10-01), None
patent: WO 9302057 (1993-02-01), None
patent: WO 9305011 (1993-03-01), None
patent: WO 9308259 (1993-04-01), None
patent: WO 9310127 (1993-05-01), None
patent: WO 9316102 (1993-08-01), None
patent: WO 9403055 (1994-02-01), None
patent: WO 9409132 (1994-04-01), None
patent: WO 9420526 (1994-09-01), None
patent: WO 9425873 (1994-11-01), None
patent: WO 9428915 (1994-12-01), None
patent: WO 9429335 (1994-12-01), None
patent: WO9511689 (1995-05-01), None
patent: WO 9512618 (1995-05-01), None
patent: WO9515309 (1995-06-01), None
patent: WO 9515309 (1995-06-01), None
patent: WO 9529691 (1995-11-01), None
patent: WO 9534538 (1995-12-01), None
patent: WO 9640263 (1996-12-01), None
patent: WO 9640858 (1996-12-01), None
patent: WO 9800439 (1998-01-01), None
patent: WO 9850046 (1998-11-01), None
patent: WO 9850066 (1998-11-01), None
patent: WO 9916864 (1999-04-01), None
patent: WO 9529190 (1999-11-01), None
Ansorge et al., “CD26/Dipeptidyl Peptidase IV in Lymphocyte Growth Regulation”Advances in Experimental Medicine and Biology421: 127-140, 1997.
Wijdenes, J., “Monoclonal Antibodies (mAb) Against gp130 Imitating Cytokines Which use the gp130 for Signal Transduction”, 9thInternational Congress of Immunology, San Francisco, California, USA, pp. 303, 1995, The 9thInternational Congress of Immunology. Publisher: 9thInternational Congress of Immunology, San Francisco, CA, USA.
Ansorge, et al., “CD26/Dipeptidyl Peptidase IV in Lymphocyte Growth Regulation”,Advances in Experimental Medicine and Biology, 421: 127-140, 1997.
Cordes, et al., “Transition States for Hydrolysis of Acetals, Ketals, Glycosides, and Glycosylamines,” Gandour, Richard D. and Schowen, Richard L. (Eds.),Transition States of Biochemical Processes, Plenum Press, New York, N.Y., pp. 429-465, 1978.
Wijdenes, J., “Monoclonal Antibodies (mAb) Against gp130 Imitating Cytokines Which use the gp130 for Signal Transduction”, 9thInternational Congress of Immunology, San Francisco, California, USA, pp. 303, 1995.
Aguila, H.L., et al., “From Stem Cells To Lymphocytes: Biology and Transplantation”,Immun. Rev., 157:13-40, (1997).
* Austin, D.J., et al., “Proximity Versus Allostery; The Role of Regulated Protein Dimerization in Biology”,Chemistry & Biology, 1:131-136, (1994).
* Bachovchin, W.W., et al., “Inhibition of IGA 1 Proteinases From Neisseria Gonorrhoeae And Hemophilus Influenzae By Peptide Prolyl Boronic Acids”,J. Biol. Chem., 265:3738-3743 (1990).
* Bailey, P.D., “An Introduction To Peptide Chemistry”,Wiley Publishers, 1-81, (1990).
* Barton, R.W.J., et al., “Binding Of The T Cell Activation Monocional Antibody Ta1 To Dipeptidyl Peptidase IV”,J. Leukocyte Biology, 48:291-296 (1990).
Baugh, R., et al., “Role and Potential Therapeutic Value of Proteinase Inhibitors in Tissue Destruction”,Proteinases And Tumor Invation, 165:157-180 (1980).
* Blumenstein, et al., “Synthetic Non-Peptide Inhibitors of HIV Protease”Biochemical and Biophysical Research Communications163(2): 980-87, 1989.
* Bodanszky, M., “Principles Of Peptide Synthesis”,Springer-Verlag, 16: (1984).
*Bodanszky, M., “The Practice Of Peptide Synthesis”,Springer-Verlag, 21: (1984).
* Bodanzky, M., “Peptide Chemistry, A Practical Textbook”,Springer-Verlag, (1988) 1-9.
* Boros, L.G., et al., “Fluoroolefin Peptide Isosteres-Tools For Controlling Peptide Conformations”,Tetrahedron Letters, 35:6033-6036., (1994).
* Brady, L., and Dodson, G., “Reflections On A Peptide”,Nature, 368:692-693, (1994).
* Brander, et al., “Heterogeneous T Cell Responses to β-Lactam-Modified Self-Structures Are Observed in Penicillin-Allergic Individuals”J. Immunol. 155 (5):2670-2678 (1995).
* Brenchley, et al., “Towards Defining Antigens in Human Membranous Nephropathy”Nephrology, Dialysis, Transplantation7 Supp. 1:21-24, (1992).
Bristol, L.A., et al., “Characterization of a Novel Rat Thymocyte Costimulating Antigen by the Monoclonal Antibody 1.3”,J. Immunol., 148:332-338 (1992).
* Bristol, L.A., et al., “Thymocyte Costimulating Antigen is CD26 (Dipeptidyl-Peptidase IV), Co-stimulation of Granulocyte, Macrophage, T Lineage Cell Proliferation Via CD26,”J. Immunol., 149:367-372 (1992).
Bristol, et al., “Inhibition of CD26 Enzyme Activity with Pro-boropro Stimulates Rat Granulocyte/Macrophage Colony Formation and Thymocyte Proliferation In Vitro”,Blood, 85(12): 3602-3609, 1995.
* Bungy, et al., Mapping of T Cell Epitopes of the Major Fraction of Rye Grass Using Peripheral Blood Mononuclear Cells From Atopics and Non-Atopics. II. Isoallergen Clone 5A of Lolium Perenne Group I (Lol p I).Eur. J. Immunol. 24 (9):2098-2103 (1994).
* Chan, et al.,Archives of Ophthalmology113 (5):597-600 (1995).
* Chazenblak, et al., “Human Organ-Specific Autoimmune Disease”, Molecular Cloning and Expression of an Autoantibody Gene Repertoire For a Major Autoantigen Reveals an Antigenic Immunodominant Region and Restricted Immunoglobulin Gene Usage in the Target Organ,J. Clinical Investigation92 (1):62-74 (1993).
* Colowick, S., et al., “Methods In Enzymology”, pp. 220-225, vol. 46, 1979.
* Coutts, et al., “Structure-Activity Relationships of Boronic Acid Inhibitors of Dipeptidyl Peptidase IV. 1. Variation of the P2Position of Xaa-boroPro Dipeptides”,J. Med. Chem., 39: 2087-94, 1996.
* Dang, N.H., et al., “Cell Surface Modulation of CD26 By Anti-IF7 Monocional Antibody: Analysis of Surface Expression and Human T Cell Activation”,J. Immunol., 145:3963-3971 (1990).
* Darcy, et al., “Protection of Mice and Nude Rats Against Toxolasmosis by A Multiple Antigenic Peptide Construction Derived From T

Affiliated with

Also associated with

Rating

Multivalent compounds for crosslinking receptors and uses... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Multivalent compounds for crosslinking receptors and uses..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Multivalent compounds for crosslinking receptors and uses... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3397039